Skip to main content
. 2012 Oct 29;4(4):1146–1160. doi: 10.3390/cancers4041146

Table 4.

Studies on AIs as a breast cancer preventive agent.

Study Number of women Median follow up (mo) Relative Risk of ER positive cancer Population
IBIS-2 trial [32] * 6,000 accrued Recruitment Completed-Results Pending Postmenopausal and high risk
MAP3 trial [33] ** 4,560 35 0.35 (0.18-0.70) Postmenopausal and high risk

* 1.0 mg anastrozole a day for 5 years; ** 25 mg exemestane a day for 5 years.